Shire Cancer Drugs Clinical Pipeline Insight

Number of pages

For Wire/Bank transfer, contact us at

Electronic Access - Single User License
CD-ROM Mail Delivery
Hard Copy Mail Delivery
Electronic Access - Multi-User License

“Shire - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Shire. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “19” cancer drugs in clinical pipeline and majority of them are in preclinical phase. There are 5 cancer drugs by Shire which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Shire - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Shire

  1.1 Business Overview

  1.2 Shire Cancer Pipeline Overview


2. Shire Cancer Drugs in Research Phase

  2.1 Immune Checkpoint Anticancer Therapies - Shire/Symphogen

  2.2 Cancer Immunotherapies - Oncoresponse/Oregon Health & Science University


3. Shire Cancer Drugs in Preclinical Phase

  3.1 Bispecific Oncology Antibodies – NovImmune

  3.2 Monoclonal Antibody Therapeutics – AVEO

  3.3 Plasmin Inhibitor – Shire

  3.4 Tie-1 Targeted Antibodies – Shire

  3.5 Anti-Matrix Metalloproteinase Monoclonal Antibodies – Kadmon

  3.6 Therapeutic Antibodies - Biogen/Shire

  3.7 Integrin Inhibitors - 3B Pharmaceuticals


4. Shire Cancer Drugs in Phase-I

  4.1 Pacritinib

  4.2 BIIB 022

  4.3 AMG 780


5. Shire Cancer Drugs in Phase-II

  5.1 Ficlatuzumab

  5.2 Imalumab

  5.3 Seribantumab

  5.4 Istiratumab


6. Shire Cancer Drugs in Phase-III

  6.1 Rigosertib

  6.2 Trebananib

  6.3 Calaspargase Pegol


7. Marketed Cancer Drugs by Shire

  7.1 Ramucirumab (Cyramza)

  7.2 Immune Globulin (CuvitruTM, Gammagard Liquid, Gammagard S/D, HyQvia & Kiovig)

  7.3 Irinotecan Sucrosofate (Onivyde)

  7.4 Necitumumab (Portrazza)

  7.5 Pegaspargase (Oncaspar)


8. No Development Reported in Cancer Drug in Clinical Pipeline

  8.1 Anticancer Antibodies - Shire/CSIRO

  8.2 Cancer Stem Cell-Targeted Antibodies - Shire/Eclipse

  8.3 c-met Imaging Peptides - GE Healthcare

  8.4 Endothelial Cell Therapy (PVS 30200) – Shire

  8.5 Anticancer Monoclonal Antibodies – Oryzon


9. Discontinued in Cancer Drug in Clinical Pipeline

  9.1 Balsalazide

  9.2 Ganitumab

  9.3 ARB 1598

  9.4 alphaV-beta3 Receptor Antagonists – Shire

  9.5 Anticancer Therapeutics - Jerini/Merck

  9.6 Cancer Therapy - Shire BioChem 

Figure 1-1: Shire Cancer Pipeline by Phase (%)

Figure 1-2: Shire Cancer Pipeline by Phase (Number)

Figure 1-3: Shire Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Shire Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)